Paul Peter Tak, Candel Therapeutics CEO
Using herpes virus vectors, Paul Peter Tak and Carl June team up to solve the CAR-T solid tumor challenge
Paul Peter Tak’s oncolytic virus startup is jumping head-first into a new partnership, looking to tackle solid tumor CAR-Ts.
Candel Therapeutics is joining forces with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.